Trials / Completed
CompletedNCT04475107
The Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients
A Multi-center, Randomized, Double-blind, Parallel, Placebo-Controlled, Phase Ⅱ Clinical Trial to Evaluate Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 113 (actual)
- Sponsor
- Shin Poong Pharmaceutical Co. Ltd. · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
This study is a multi-center, randomized, double-blind, parallel, placebo-controlled, phase Ⅱ clinical trial to evaluate efficacy and safety of Pyramax in mild to moderate COVID-19 patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pyronaridine-Artesunate | Pyramax |
| DRUG | Placebo | Placebo |
Timeline
- Start date
- 2020-07-09
- Primary completion
- 2021-03-25
- Completion
- 2021-04-15
- First posted
- 2020-07-17
- Last updated
- 2021-06-01
Locations
13 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT04475107. Inclusion in this directory is not an endorsement.